The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF) (“Flowr” or the
“Company”), a Canadian licensed producer of premium cannabis
products, today announced the promotion of Jason Broome to the role
of Chief Research and Innovation Officer (CRIO). Mr. Broome
previously served as Senior Vice President of Operations.
As CRIO, Mr. Broome will develop new high-quality products and
lead Flowr’s research into cultivars, form factors and delivery
systems for the global markets. He will also oversee Flowr’s
state-of-the-art R&D facility, part of an exclusive partnership
with Hawthorne Canada, a subsidiary of The Scott's Miracle-Gro
Corporation (NYSE: SMG).
“Flowr’s product innovation portfolio must meet the world-class
standards of our cultivation,” said Tom Flow, Flowr's Co-CEO. “It’s
an unusually demanding ask, but Jason’s expertise across all
aspects of product development, from molecule to market, is unique
and yet totally in keeping with Flowr’s high-performance,
high-creativity culture.”
Over a 15-year career in the pharmaceutical industry, Mr. Broome
led the commercialization of major pharmaceutical brands and built,
operated and sold several healthcare-related companies, bringing
disruptive technologies and systems to market. Within the cannabis
sector, he was co-founder of the first company licensed to
cultivate and extract hemp in the state of Kentucky and COO of a
Colorado manufacturer of CBD oil. He holds a master’s degree in
Molecular Genetics from the University of Ottawa.
Mr. Broome’s appointment is a natural and dynamic step forward
for Flowr, working closely with Dr. Lyle Oberg, Chief Policy and
Medical Officer, and in line with the recent hiring of Dr. Deron
Caplan, North America’s first cannabis cultivation Ph.D., and Chef
Ryan Reed, both to the Company’s R&D department.
About Flowr
Flowr, through its subsidiaries, holds a cannabis production and
sales licence granted by Health Canada. With a head office in
Toronto and a production facility in Kelowna, BC, Flowr builds and
operates large-scale, GMP-designed cultivation facilities utilizing
its own patented growing systems. Flowr’s investment in research
and development along with its sense of craftsmanship and a spirit
of innovation is expected to enable it to provide premium-quality
cannabis that appeals to the adult-use recreational market and
addresses specific patient needs in the medicinal market.
For more information, visit www.flowr.ca. Follow Flowr
on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram:
@flowrcanada; and LinkedIn: The Flowr Corporation
On behalf of The Flowr Corporation:
Tom Flow
Co-CEO and Director
Forward-Looking Information
This press release includes forward-looking information within
the meaning of Canadian securities laws regarding Flowr and its
business, which may include, but are not limited to: the facilities
described herein, including, without limitation, the timing of
construction and completion thereof, the expertise and experience
of Mr. Broome, Mr. Broome developing new high-quality products, Mr.
Broome leading Flowr’s research into cultivars, form factors and
delivery systems, Mr. Broome overseeing Flowr’s state-of-the-art
R&D facility, Flowr’s vision to be on the cutting edge of
cultivation, Flowr’s world class standards in cultivation, Flowr
developing new products for global markets, Flowr’s R&D program
and its focus on improving cultivation techniques and systems and
developing cannabis plants that produce the highest quality flower
and address specific needs in the medical and recreational markets,
Flowr’s focus on producing premium quality cannabis at scale, the
addition of Mr. Broome and the alliance with Hawthorne Canada
strengthening Flowr’s position at the forefront of understanding
the tools and techniques needed to grow great cannabis, the belief
that Flowr’s R&D team and its partnership with Hawthorne
uniquely positions Flowr to address genetic intricacies that drive
the unique consumer experience produced by each strain and to
cultivate a strain to maximize the natural expression of those
genetics through its chemical components, Flowr’s intention to
develop and test Hawthorne cultivation systems in the R&D
facility, Flowr’s investment in research and development along with
its sense of craftsmanship and a spirit of innovation enabling it
to provide premium-quality cannabis that appeals to the adult-use
recreational market and addresses specific patient needs in the
medicinal market and other factors. Often, but not always,
forward-looking information can be identified by the use of words
such as “plans”, “is expected”, “expects”, “scheduled”, “intends”,
“contemplates”, “anticipates”, “believes”, “proposes”
or variations (including negative and grammatical variations)
of such words and phrases, or state that certain actions, events or
results “may”, “could”, “would”, “might” or “will” be taken, occur
or be achieved. Such statements are based on the current
expectations of Flowr’s management and are based on assumptions and
subject to risks and uncertainties. Although Flowr’s management
believes that the assumptions underlying these statements are
reasonable, they may prove to be incorrect. The forward-looking
events and circumstances discussed in this press release may not
occur by certain specified dates or at all and could differ
materially as a result of known and unknown risk factors and
uncertainties affecting Flowr, including risks relating to Flowr’s
inability to construct the facilities described herein, or in the
time anticipated, Flowr’s inability to grow cannabis at scale,
which could adversely impact revenues, the fact that the facilities
described herein may not include all the elements described in this
press release, which could adversely impact the partnership with
Hawthorne, Flowr’s R&D strategy and/or Flowr’s revenues,
the inability of Flowr to test Hawthorne’s cultivation systems,
which could adversely impact the partnership described herein and
future R&D initiatives of Flowr, Flowr not being able to
sustain its competitive advantage in cultivation and being unable
to remain at the forefront of industry innovation, whether as a
result of failed construction of the facilities described herein or
otherwise, Flowr’s inability to research genetics and cultivation
data analytic systems, Flowr not being able to meet demand or
fulfill purchase orders, which could materially impact revenues and
its relationships with purchasers, Mr. Broome not bringing the
experience or expertise described herein, Mr. Broome being unable
to develop new high-quality products, Mr. Broome being unable to
lead Flowr’s research into cultivars, form factors and delivery
systems, Mr. Broome being unable to oversee Flowr’s
state-of-the-art R&D facility, Flowr not being able to remain
at the cutting edge of cultivation or maintain world-class
standards for cultivation, Flowr’s R&D program not improving
cultivation techniques and systems and not developing cannabis
plants that produce the highest quality flower and address specific
needs in the medical and recreational markets, which could result
in Flowr losing its competitive edge and/or sales, the addition of
Mr. Broome and the alliance with Hawthorne Canada not strengthening
Flowr’s position at the forefront of understanding the tools and
techniques needed to grow great cannabis or bring new products to
market, which could significantly impact Flowr’s competitive edge
with respect to cultivation, Flowr requiring additional financing
from time to time in order to continue its operations and such
financing may not be available when needed or on terms and
conditions acceptable to the Company, new laws or regulations
adversely affecting the Company’s business and results of
operations, results of operation activities and development of
projects, project cost overruns or unanticipated costs and
expenses, the inability of Flowr’s products to be high
quality, the inability of Flowr to produce and distribute premium,
high quality products, the inability to supply products or any
delay in such supply, Flowr’s securities, the inability to generate
cash flows, revenues and/or stable margins, the inability to grow
organically, risks associated with the geographic markets in which
Flowr operates and/or distributes its products, risks associated
with fluctuations in exchange rates (including, without limitation,
fluctuations in currencies), risks associated with the use of
Flowr’s products, the cannabis industry and the regulation thereof,
the failure to comply with applicable laws, risks relating to
partnership arrangements, possible failure to realize the
anticipated benefits of partnership arrangements, product launches
(including, without limitation, unsuccessful product launches), the
inability to launch products, the failure to obtain regulatory
approvals, economic factors, market conditions, risks associated
with the acquisition and/or launch of products, the equity and debt
markets generally, risks associated with growth and competition
(including, without limitation, with respect to Flowr’s products),
general economic and stock market conditions, risks and
uncertainties detailed from time to time in Flowr’s filings with
the Canadian Securities Administrators and many other factors
beyond the control of Flowr. Although Flowr has attempted to
identify important factors that could cause actual actions, events
or results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. No forward-looking information can be
guaranteed. Except as required by applicable securities laws,
forward-looking information speaks only as of the date on which it
is made and Flowr undertakes no obligation to publicly update or
revise any forward-looking information, whether as a result of new
information, future events, or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
-ends -
Media: Rebecca Brown
Crowns
+1-647-456-5599
rebecca@crowns.agency
For Investors Only: Bram Judd
The Flowr Corporation
+1.905.940.3993 ext.1520
bram@flowr.ca
The Flowr (TSXV:FLWR)
Historical Stock Chart
From Feb 2024 to Mar 2024
The Flowr (TSXV:FLWR)
Historical Stock Chart
From Mar 2023 to Mar 2024